Summary of AVITA Medical FY Conference Call Company Overview - **Company**: AVITA Medical (NasdaqCM:RCEL) - **Industry**: Acute wound care, specifically focused on hospital-based treatments for burns, surgical wounds, and traumatic wounds [2][3] Core Products - **RECELL**: Flagship product for acute wound care, evolving from a manual to an automated process (RECELL GO and RECELL GO mini) [4][5] - **Cohealyx**: Collagen dermal matrix that prepares the wound bed for grafting, offering quicker vascularization compared to competitors [5][6] - **PermeaDerm**: Temporary biosynthetic matrix that protects and allows observation of the wound during healing [6][7] Market Dynamics - **Target Market**: Approximately 200 accounts in the U.S. with a Total Addressable Market (TAM) of $3.5 billion, focusing on a strategic TAM of $1.3 billion [11] - **Market Penetration**: Currently less than 5% across the portfolio, with RECELL at about 15% penetration [11][12] - **International Expansion**: Efforts in Australia, Japan, and Europe, with recent attention due to a Swiss nightclub fire highlighting the need for better treatment options [12][13] Financial Performance - **Growth Rate**: Achieved 11% growth in the previous year despite challenges, with expectations for sequential growth throughout 2026 [14][15] - **CAGR**: Company has experienced a compound annual growth rate of close to 30% over the last five years [14] - **Cost Management**: Focus on cost discipline while aiming for revenue growth, with strategic reductions in the sales force [15][16] Reimbursement Challenges - **Reimbursement Dynamics**: Ongoing issues with reimbursement from CMS and MACs, with about 70%-80% recovery expected in the near term [30][35] - **Impact on Sales**: Delays in reimbursement have caused confusion and disruption, but clarity is expected to improve in the coming months [33][34] Strategic Focus - **Product Adoption**: Emphasis on increasing penetration in existing accounts and expanding usage among different types of wounds and physicians [40][61] - **Clinical Studies**: Ongoing post-market studies for Cohealyx and PermeaDerm, with results expected to support product adoption [7][13] - **Sales Strategy**: A clinically based sales team that acts as consultants to surgeons, enhancing familiarity with products [62][63] Economic Benefits - **Speed to Healing**: RECELL allows patients to heal and be discharged 36% sooner, providing economic advantages for hospitals [53][72] - **Cost Savings**: Transitioning from allograft to PermeaDerm can save hospitals significant costs, as highlighted by a physician's estimate of $500,000 in annual savings [87] Profitability Outlook - **Margin Expectations**: Cohealyx and PermeaDerm expected to have around 50% margins, while RECELL will maintain higher margins in the low 80s [92] - **Path to Profitability**: Anticipated growth trajectory suggests that profitability is on the horizon if current trends continue [93] Conclusion - **Future Outlook**: AVITA Medical is positioned for growth with a strong focus on execution and product adoption, expecting to discuss improved financial metrics throughout the year [97]

Core Insights - The company aims for progressive revenue growth in 2026, targeting revenue between $80 million and $85 million after a challenging 2025 [3][4][5] Financial Performance - The gross margin for 2025 was reported at 82.1%, with a forecast of 83% to 85% for 2026, driven by expected growth in RECELL products [1][6][7] - Revenue for 2025 was $71.6 million, including $17.6 million in Q4, with a stable growth outlook of 12% to 19% for 2026 [2][3] Operational Strategy - The company has focused on disciplined execution in cash management, headcount, and forecasting to enhance predictability and performance in 2026 [4][5] - A new $60 million credit facility was established to reset revenue and cash covenants, allowing for improved financial flexibility [6][15][16] Product Focus - The company is prioritizing its three-product platform, which includes RECELL, RECELL GO, Cohealyx, and PermeaDerm, aiming to increase utilization and adoption [12][17] - The commercialization of vitiligo has been deprioritized due to uncertain reimbursement conditions, with a focus on core product adoption instead [6][17] Sales and Market Strategy - The sales force has been restructured to focus on 200 key accounts, including burn centers and trauma centers, to drive growth in existing relationships [11][12] - The company is navigating reimbursement challenges, with updates on Medicare rates expected to improve the sales environment [9][10]

Core Insights - AVITA Medical, Inc. is a leading company in therapeutic acute wound care, focusing on innovative solutions for wound healing [3] Group 1: Company Participation - AVITA Medical management will participate in the TD Cowen 46th Annual Health Care Conference in Boston, MA, with Cary Vance as Interim CEO and David O'Toole as CFO [1] - A presentation and fireside chat is scheduled for March 4 at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time, with a live and archived webcast available on the company's website [2] Group 2: Product Offerings - The company's flagship product, RECELL, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ for enhanced clinical outcomes [3] - In the U.S., AVITA Medical holds exclusive rights to manufacture and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3] Group 3: International Approvals - RECELL is approved for various applications in international markets, including thermal burn and trauma wounds, and has received CE mark in Europe, TGA registration in Australia, and PMDA approval in Japan [4]

Summary of AVITA Medical Conference Call Company Overview - **Company**: AVITA Medical (NasdaqCM:RCEL) - **Date of Call**: February 18, 2026 Key Points Financial Performance - **2025 Revenue**: $71.6 million, representing an 11% growth compared to the previous year [8] - **Q4 Revenue**: $17.6 million, showing stability with a slight increase from $17 million in Q3 [3] - **2026 Revenue Guidance**: Expected to be between $80 million and $85 million, indicating progressive quarter-over-quarter growth [3][8] - **Gross Profit Margin**: 82.1% for the year, with a slight decrease to 81% in Q4 due to inventory reserves and product mix impacts [8][10] - **Operating Expenses**: Reduced to a normalized range of $23-$24 million, with a focus on maintaining disciplined cost management [11][52] Strategic Focus - **Execution and Growth**: The company aims for disciplined execution and progressive revenue growth in 2026, focusing on understanding customer needs and improving forecasting accuracy [1][2] - **Sales Force Optimization**: The sales force has been restructured to focus on 200 key accounts, including 120+ burn centers and 50-60 level one trauma centers [4][5] - **Product Portfolio**: The company has three products—RECELL, Cohealyx, and PermeaDerm—each facing unique challenges in market adoption [5][18] Market Dynamics - **Reimbursement Challenges**: The company has made progress in resolving reimbursement issues, with six out of seven Medicare Administrative Contractors (MACs) having published their rates [6][7] - **Product Adoption**: Efforts are ongoing to increase the utilization of RECELL among existing physicians and expand its use to new cases and accounts [20][21] - **International Expansion**: The company is making inroads in international markets, including Japan and Australia, with plans for RECELL GO approval [26][27] Future Outlook - **Path to Profitability**: The company aims to achieve cash flow breakeven through revenue growth and disciplined operating expenses, without the need for additional equity funding in the near term [51][52] - **Focus on Vitiligo**: The commercial effort for vitiligo has been deprioritized due to uncertain reimbursement and low economic viability [54][55] - **Long-term Growth**: The company expects to return to a compound annual growth rate (CAGR) of 20%-30% in the coming years, with a focus on stabilizing operations and reducing distractions [12][62] Additional Insights - **Credit Facility**: A new credit facility with Perceptive Advisors has been established to reset revenue covenants, providing more flexibility for future growth [15][16] - **Market Positioning**: The company is focused on leveraging clinical data and physician relationships to enhance product adoption and compete against existing alternatives [46][48] - **Management's Commitment**: The management team is dedicated to growing the company independently and is not currently seeking acquisition opportunities [57] This summary encapsulates the key insights and strategic directions discussed during the AVITA Medical conference call, highlighting the company's financial performance, market strategies, and future growth plans.

AVITA Medical®, Inc | Cary Vance, Interim CEO J.P. Morgan Healthcare Conference (ASX: AVH, NASDAQ: RCEL) Forward-Looking Statements & Legal Disclaimers This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward-looking stat ...

Summary of AVITA Medical FY Conference Call (December 04, 2025) Company Overview - **Company**: AVITA Medical (NasdaqCM:RCEL) - **Industry**: Therapeutic acute wound care - **Focus**: Acute wounds such as burns, gunshot wounds, and road rashes, aiming to expedite patient recovery and hospital discharge [2][3] Core Products - **RECELL**: First-in-class spray-on skin cell product approved by the FDA in 2019, used in burn centers and trauma centers across the U.S. [4] - **Cohelix**: Collagen-based dermal matrix, bioengineered in partnership with Regenity, which reduces gross margin but increases operating margin [6] - **PermeaDerm**: Biosynthetic dressing that allows visibility of the wound without removal, facilitating air exchange [6] Key Data and Performance Metrics - **RECELL Efficacy**: Patients using RECELL can be discharged 36% faster, with a study of 6,300 burn patients showing a six-day earlier discharge compared to traditional methods [4][17] - **Cost Discipline**: Achieved $10 million in annual cost reductions, maintaining SG&A costs for growth [5] - **Revenue Impact**: Estimated revenue loss of $10-$12 million due to reimbursement issues, with a focus on regaining momentum in 2026 [11][13] Market Potential - **Total Addressable Market (TAM)**: Estimated at $3.5 billion, with AVITA currently capturing about 5% of this market [17] - **Market Share**: Approximately 15%-20% market share in burn centers after five years of presence [17] Financial Performance - **Revenue**: Reported $17 million in revenue, down 13% year-over-year, primarily due to reimbursement challenges [19] - **Gross Margin**: RECELL products maintain a gross margin of 84%, though overall margins may decrease due to the mix of products sold [19][20] - **Cost Management**: Reduced expenses by 24% year-over-year, with a target of $23 million in expenses moving forward [20] Future Outlook - **2026 Guidance**: Anticipated revenue guidance to be provided in early January, with expectations of returning to a growth rate of 29% [20][21] - **International Expansion**: RECELL GO approved in the EU and UK, with pending approval in Australia, utilizing third-party distributors for market entry [15] Additional Insights - **Reimbursement Challenges**: Ongoing issues with CMS and MACs have impacted product usage and demand, but resolution efforts are underway [12][13] - **Patient-Centric Focus**: Emphasis on improving patient outcomes and reducing healthcare costs associated with prolonged hospital stays [16] This summary encapsulates the key points from the AVITA Medical FY Conference Call, highlighting the company's focus on acute wound care, product efficacy, market potential, financial performance, and future outlook.

Company Overview - AVITA Medical, Inc. (NASDAQ: RCEL) specializes in full-thickness wound reconstruction with a comprehensive product portfolio [1] - The company offers RECELL and RECELL GO for point-of-care autologous "Spray-On Skin" applications [1] - Additional products include Cohealyx for graft-ready dermis and PermeaDerm as a protective biosynthetic cover, developed in partnership [1] Leadership and Expertise - Myriam Hernandez Alvarez holds multiple degrees in Electronics and Telecommunication Engineering, Computer Science, Business Management, and Computer Applications, showcasing a strong academic background [1]

Company Overview - AVITA Medical, Inc. (NASDAQ: RCEL) specializes in full-thickness wound reconstruction with a comprehensive product portfolio [1] - The company offers RECELL and RECELL GO for point-of-care autologous "Spray-On Skin" applications [1] - Additional products include Cohealyx for graft-ready dermis and PermeaDerm as a protective biosynthetic cover, developed in partnership [1]

Group 1: Pilbara Minerals (ASX: PLS) - Morgan Stanley increased its stake in Pilbara Minerals from 7.3% to 9.0% [3] - AustralianSuper raised its holding from 15.69% to 17.54% [4] - Pilbara Minerals reported a slight increase in spodumene concentrate production to 755,000 tons, a 4% year-on-year growth, but revenue decreased by 39% to AUD 769 million due to a 43% drop in actual prices [4] - The company maintains a strong balance sheet with approximately AUD 1 billion in cash and AUD 1.6 billion in total liquidity [4] - CEO Dale Henderson believes that despite short-term market volatility, the long-term fundamentals of the lithium industry remain strong, indicating potential supply tightness in the future [5] Group 2: Bubs Australia (ASX: BUB) - Bubs Australia appointed Paul Jensen as the new chairman and Joe Coote as the managing director and CEO [11] - The company achieved its first profit and surpassed AUD 100 million in revenue in the fiscal year [11] - Bubs has seen a 50% increase in its stock price this year, with a focus on expanding into the U.S. market [12] - Jensen aims to ensure the board has the right skills and experience to implement the company's strategy [12] Group 3: Avita Medical (ASX: AVH) - Avita Medical announced that its RECELL GO product received CE marking under EU medical device regulations [17] - The product is expected to support treatment for acute wound injuries in European burn centers [17] - Following the announcement, Avita Medical's stock surged by 10.08% [17] Group 4: Resolution Minerals (ASX: RML) - Resolution Minerals reported significant results from soil sampling at its Horse Heaven project, with samples showing up to 49.8% antimony and 1,420 g/t silver [22] - The stock price increased by 25%, with a year-to-date gain of 650% [22] - The project is adjacent to Perpetua Resources' large antimony-gold project, indicating strong potential [22] Group 5: Theta Gold Mines (ASX: TGM) - Theta Gold Mines has commenced construction on its flagship TGME gold project in South Africa, with significant earthworks and infrastructure development underway [25] - The company has secured contracts with leading construction firms and aims to employ 70% of its workforce from local communities [25][28] - The project is expected to begin production in Q1 2027, with an estimated annual output of 110,000 ounces of gold in the first three years [25][36] - The total cost for earthworks and construction is estimated at USD 10 million (approximately AUD 15 million) [34]

Core Insights - AVITA Medical has received the CE Mark for its RECELL GO device, allowing commercialization in Europe and other CE Mark-recognizing markets [1][2] - The RECELL GO device enables healthcare professionals to prepare a suspension of a patient's own skin cells to promote healing in burns and traumatic or surgical wounds [2] - Clinical data presented at the 2025 European Burns Association Congress showed a 36% reduction in hospital stays for adults with deep partial-thickness burns treated with RECELL compared to traditional grafting [3] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on optimizing wound healing and accelerating patient recovery [5] - The RECELL System, which includes RECELL GO, is approved by the U.S. FDA for treating thermal burn and trauma wounds, utilizing a patient's own skin to create Spray-On Skin™ Cells [5][6] - In addition to RECELL, AVITA Medical holds exclusive rights to manufacture and distribute PermeaDerm and Cohealyx™, enhancing its product portfolio in wound care [5]